Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;14(4):340-4.
doi: 10.3779/j.issn.1009-3419.2011.04.07.

[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients]

[Article in Chinese]
Zhiqiang Gao  1 , Baohui Han, Jie Shen, Aiqin Gu, Hua Zhong
Affiliations

[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients]

[Article in Chinese]
Zhiqiang Gao et al. Zhongguo Fei Ai Za Zhi. 2011 Apr.

Abstract
in English, Chinese

Background and objective: It has been proven that ribonucleotide reductase M1 (RRM1) expression level was closely related to gemcitabine drug-resistance to tumor cells. The aim of this study is to explore the relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.

Methods: The expressions of RRM1 in 75 advanced NSCLC tissues were qualitatively detected by immunohistochemical methods. Seventy-five patients had received gemcitabine and cisplatin (GP) chemotherapy regimen. General characteristics of patients, response to treatment, efficacy evaluation and survival time were retrospectively investigated. Differences between the groups were statistically analysed by chi-square test. Survival differences were analysed by temporal inspection and Kaplan-Meier survival curves.

Results: RRM1 protein expression rate was 38.7%. RRM1 protein expression had no obvious relationship with gender, age, smoking status, and the clinical stages and histopathological types (P > 0.05). Response rate in RRM1 protein high expression groups (31.3%) was remarkably lower than that in low expression groups (41.3%), the difference was statistically significant (P=0.005). 1-year survival rate in RRM1 protein high expression groups (27.6%) was remarkably lower than that in low expression group (58.7%), the difference was statistically significant (P=0.009). No significant different of median survival was observed between RMM1 protein high expression group and low expression group (P >0.245). Time to progression in RRM1 protein high expression groups (3.10 months) was remarkably lower than that in low expression group (5.11 months), the difference was statistically significant (P=0.042).

Conclusions: RRM1 protein expression levels are closely related to effects of gemcitabine and cisplatin chemotherapy and prognosis of advanced NSCLC patients.

背景与目的: 核糖核苷酸还原酶M1（ribonucleotide reductase M1, RRM1）的表达水平与肿瘤细胞对吉西他滨耐药密切相关。本研究旨在探讨晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）中RRM1蛋白的表达水平与吉西他滨联合顺铂（GP方案）化疗疗效的关系。

方法: 应用免疫组织化学染色法检测75例晚期NSCLC组织中的RRM1蛋白表达，75例患者均接受GP化疗方案，回顾调查患者的一般特征、治疗反应、疗效评价及生存时间。组间差异采用卡方检验，采用Kaplan-Meier法进行生存分析。

结果: RRM1蛋白表达阳性率为38.7%，与患者的性别、年龄、吸烟状态、临床分期及组织病理学类型无明显相关性（P > 0.05）；RRM1蛋白高表达组的化疗有效率（31.1%）低于低表达组（41.3%），有统计学意义（P=0.005）；RRM1高表达组的1年生存率（27.6%）低于低表达组（58.7%），有统计学意义（P=0.009）；RRM1蛋白高表达组的中位生存期（10.70个月）低于低表达组（13.30个月），但无统计学差异（P=0.245）；RRM1蛋白高表达组的疾病进展时间（3.10个月）低于低表达组（5.11个月），差异有统计学意义（P=0.042）。

结论: 晚期NSCLC患者组织中RRM1蛋白的表达水平与GP方案化疗的疗效及预后密切相关。

PubMed Disclaimer

Figures

1
1
RRM1蛋白在晚期NSCLC组织中的表达（SP，×200）。A：阳性表达；B：阴性表达。 Expression of RRM1 in advanced NSCLC tissues (SP, ×200). A: Positive; B: Negative.
2
2
RRM1表达水平与NSCLC患者的生存曲线之间的关系。A：总体生存时间；B：疾病进展时间。 Relationships between expressions of RRM1 and the survival curves of NSCLC patients. A: overall survival; B: time to progression.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249. doi: 10.3322/caac.20006. - DOI - PubMed
    1. Aggarwal C, Somaiah N, Simon GR, et al. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw. 2010;8(7):822–832. doi: 10.6004/jnccn.2010.0059. - DOI - PubMed

    1. Arora A, Siddiqui IA, Shukla Y, et al. Modulation of p53 in 7, 12-dimethylbenz[a] anthracene-induced skin tumors by diallyl sulfde in Swiss albino mice. Mol Cancer Ter, 2004, 3(11): 1459-1466.

    1. Adams VR, Harvey RD. Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology. http://europepmc.org/abstract/MED/20044377 Am J Health Syst Pharm. 2010;67(1 Suppl 1):S3–S9. - PubMed
    1. Rosell R, Cobo M, Isla D, et al. Pharmacogenomics and gemcitabine. https://www.researchgate.net/publication/6978135_Pharmacogenomics_and_ge.... Ann Oncol. 2006;17(suppl 5):v13–v16. - PubMed

MeSH terms